Russell Investments Group Ltd. lifted its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 190.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 283,910 shares of the company’s stock after acquiring an additional 186,294 shares during the quarter. Russell Investments Group Ltd.’s holdings in Twist Bioscience were worth $54,863,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Western Wealth Management LLC purchased a new position in Twist Bioscience in the first quarter worth $31,000. Root Financial Partners LLC bought a new position in Twist Bioscience in the 3rd quarter valued at $33,000. PNC Financial Services Group Inc. increased its position in shares of Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the last quarter. Fifth Third Bancorp purchased a new stake in shares of Twist Bioscience during the 1st quarter valued at $54,000. Finally, Allworth Financial LP purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at $62,000.
Insider Buying and Selling
In related news, SVP Paula Green sold 10,088 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the sale, the senior vice president owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. This represents a 8.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 356,546 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the completion of the transaction, the chief executive officer owned 620,589 shares of the company’s stock, valued at approximately $98,046,856.11. This represents a 36.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 495,279 shares of company stock valued at $80,489,387 in the last ninety days. 3.08% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. Royal Bank Of Canada set a $137.00 target price on Twist Bioscience in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Canaccord Genuity Group reduced their price target on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating for the company in a research report on Friday. Piper Sandler raised their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Finally, TD Cowen decreased their price objective on shares of Twist Bioscience from $190.00 to $137.00 and set a “buy” rating for the company in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $141.00.
Get Our Latest Stock Analysis on Twist Bioscience
Twist Bioscience Price Performance
Twist Bioscience stock opened at $111.60 on Monday. The firm has a 50 day simple moving average of $150.23 and a 200 day simple moving average of $93.07. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $219.71. The firm has a market capitalization of $7.00 billion, a price-to-earnings ratio of -53.40 and a beta of 2.25.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. The firm had revenue of $126.64 million for the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business’s quarterly revenue was up 26.7% on a year-over-year basis. On average, analysts predict that Twist Bioscience Corporation will post -1.52 earnings per share for the current year.
Key Twist Bioscience News
Investors following TWST have been watching these news items:
- Positive Sentiment: Fiscal Q4 revenue rose about 27% year over year to $126.6 million, beating consensus, while the $0.32-per-share loss was narrower than analysts expected. AI drug-discovery revenue totaled $59.1 million for fiscal 2026. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
- Positive Sentiment: Fiscal Q1 2027 revenue guidance of $130 million–$132 million is above the $126.3 million consensus estimate. Article: Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
- Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is only modestly above the $549 million consensus, which may have disappointed investors looking for a stronger outlook. Article: Twist Bio slips despite Q4 beat after underwhelming FY27 outlook
Twist Bioscience Company Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Featured Articles
- Five stocks we like better than Twist Bioscience
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
